chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Arm Pain - Near Injection Site; Swelling - Near Injection Site; Redness - Near Injection Site; Rash - Near Injection Site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Arm Pain - Near Injection Site), VACCINATION SITE SWELLING (Swelling - Near Injection Site), VACCINATION SITE ERYTHEMA (Redness - Near Injection Site) and VACCINATION SITE RASH (Rash - Near Injection Site) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013A21A) for COVID-19 vaccination.     Concurrent medical conditions included Cholesterol and Diabetes. Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN) for Cholesterol, METFORMIN and DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE (FARXIGA) for Diabetes.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, the patient experienced VACCINATION SITE PAIN (Arm Pain - Near Injection Site), VACCINATION SITE SWELLING (Swelling - Near Injection Site), VACCINATION SITE ERYTHEMA (Redness - Near Injection Site) and VACCINATION SITE RASH (Rash - Near Injection Site). The patient was treated with IBUPROFEN ongoing from 06-Mar-2021 for Pain management, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (Arm Pain - Near Injection Site), VACCINATION SITE SWELLING (Swelling - Near Injection Site), VACCINATION SITE ERYTHEMA (Redness - Near Injection Site) and VACCINATION SITE RASH (Rash - Near Injection Site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Other concomitant medication included thyroid medication. ibuprofen is used as treatment medication.
I started getting spots on my legs and they started getting bigger. Eventually they started going away. They hurt and were very itchy. I contacted my doctor, and they recommended me to a Dermatologist. I went to the Dermatologist, and they prescribed Mometasone FUROATE Cream, but it did not work. I tried Betamethasone, but it didn't work either. I am still dealing with this at this time, and it itches. I am taking BENADRYL to help moderate it. If I take a shower the itching becomes severe. Now I have been referred to an Allergist.
pt recv vax;T 103R;tepid bath & apap given;sz & v;to PMD;ordered ATBs,possible URI; T 102; to er;extreme fussiness;rash on back, face & stomach,raised,blotchy, very red;T100; nl behavior 10apr;
Itching on the left arm near the site of the injection. area covered over 3-4 inches in length to 2 inches in width. red and hot. Notice on 1-21-21 around 10pm, could not find my anti itch cream to apply to site.  Next day  on 1-22-21 notice it again around 11 am it was red and hot to touch. Itching again. but I would not scratch it . Finally found the anti itch cream and applied this to the area. An hour later it was still hot but seemed to look better. Still trying to get to the hospital Clinic to have it checked out.....
Information has been received from a physician concerning of 13 year old female who in 1995 was vaccinated with a dose of varicella virus vaccine live. On 08Jan06, the pt developed shingles. She was seen by a doctor on 09Jan06 and referred to an eye specialist. The shingles appeared to affect the facial nerve. The shingles were on her face, lips, inside her mouth and her left eye. There was no corneal or iris involvement as determined by the eye specialist. The eyelid blistered and she had conjunctivitis that was being treated with bacitracin zinc (+) neomycin sulfate (+) polymyxin B sulfate (Neosporin) opthalmic ointment and oral acyclovir. At the time of the report, the pt had not recovered. A product quality complaint was not involved. Follow up information was received from the physician who reported that the pt did not have an adverse reaction. She had shingles. Additional information was received from the physician who reported that the pt has fully recovered. There was no further information to report.
Myalgia, NauseaVomiting, loss of appetite, fatigued, achey Narrative:
4/3/07 pt developed asymptomatic parotitis community has had 4 documented cases of mumps as of 4/15/07 in college students.
Information has been received from a licensed practical nurse concerning an unspecified patient (age and gender unknown). The nurse reported that on an unspecified date, an unspecified patient may have received one of the improperly stored lots, but she was not sure which of the vaccines the unspecified patient received. Names of vaccines involved: PROQUAD lot # M044720, expiration date 07-MAY-2018, (dosage and route of administration not provided) or VARIVAX lot #M017290, expiration date 07-APR-2018, (dosage and route of administration not provided). The vaccines were reconstituted with Merck sterile water diluent (lot number not provided) which was not improperly stored. Temperature: In the range 15°F to 46°F Time frame: 17 hours Previous temperature excursion: No Data logger involved: Yes. No adverse effects reported. No additional information was provided. Additional information has been requested.
Patient received second dose of vaccine, but half the dose squeezed out of the syringe. Moderna recommended giving  a second dose if more than half the vaccine was lost, which the patient believed it was.
Per pt 30 or more lesions, headache, no fever, just didn't feel too well. Resolved prior to pt reporting.
unable to smell; taste was off; injection site was sore; nose was tingly; A spontaneous report was received from a consumer concerning a female patient who received Moderna's COVID-19 vaccine and experienced injection site soreness, nose tingling, loss of smell, and altered taste.    The patient's medical history was not provided. No relevant concomitant medications were reported.   On 05 Jan 2021, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection.   On 05 Jan 2021, the patient experienced soreness at the injection site. A short while after the vaccine, her nose began to feel tingly. Later that evening (8:30 pm), the patient was unable to smell the Crystal Light she was drinking and the taste was off. On 06 Jan 2021, she reported having to be close to her coffee to smell it. No treatment information was provided.   Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the events was unknown/not reported; Reporter's Comments: This case concerns a female of unknown age who experienced nonserious events of unexpected nasal discomfort, anosmia, taste disorder and expected vaccination site pain. Event onset the same day as the first dose of mRNA-1273. Treatment not reported. Event outcomes unknown. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
This report to VAERS provides the following narrative: A report from VAERS (Health Authority) concerns a 21 year old male. The patient's concurrent disease included URI. Patient received FLUMIST (intranasal) on 25-Feb-2009. Patient developed Guillain Barre Syndrome - Miller Fisher Syndrome after multiple vaccinations. Patient had symptoms like Neuropathy, Weakness, Hyporeflexia, Headache, Migraine, Muscle Pain. On 27-Jul-2009 multiple records received including hospital records and follow-up consults. Patient presented with complaints of weakness in legs, lower back pain and stumbling gait as well as diplopia, dysarthria, paresthesias of the fingertips. PE positive for facial nerve paresis, leg weakness, wide-based gait, ataxia with absent DTRs. Treatment with IVIG with partial resolution. Transferred to rehab with continued H/A and back pain. MRI brain positive for sinus thickening. At the time of reporting, the Miller Fisher syndrome and Guillain Barre syndrome were ongoing. The reporter considered the Miller Fisher syndrome and Guillain Barre syndrome to be serious due to hospitalization.
I had a positive Covid 11/11/20. My main symptom was loose stools x 3 weeks
Improper storage of product in use; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. The patient's pertinent medical history, concomitant medication, previous drug reactions, and allergies were not reported.      On 15-MAR-2021, the patient was vaccinated with one Hepatitis A Vaccine, Inactivated (VAQTA) (lot number T014589, which has been verified to be valid, the expiration date was reported and validated as 25-OCT-2021), as prophylaxis (dose, dose number, route of administration, and anatomical site of vaccination were not provided).  The suspect vaccine was exposed to a temperature of 0 hours 30 minutes and 0 seconds (product storage error), as recorded by digital data logger. Additionally, a previous temperature excursion was reported of 46.4 degrees F for a time frame of 0 hours 30 minutes and 0 seconds. The reporter stated all the patients were asymptomatic.  This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); devicelotnumber: T014589; expirationdate: 25-OCT-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent; Sender's Comments:  US-009507513-2104USA001297:
sharp dizziness; cold burning flesh feeling; trouble breathing; throat was tingly; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (sharp dizziness), COLD BURN (cold burning flesh feeling), DYSPNOEA (trouble breathing) and PHARYNGEAL PARAESTHESIA (throat was tingly) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017B21A) for COVID-19 vaccination.     The patient's past medical history included Hives.  relevant concomitant products usage were not reported by the reporter.    On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, the patient experienced DIZZINESS (sharp dizziness), COLD BURN (cold burning flesh feeling), DYSPNOEA (trouble breathing) and PHARYNGEAL PARAESTHESIA (throat was tingly). At the time of the report, DIZZINESS (sharp dizziness), COLD BURN (cold burning flesh feeling), DYSPNOEA (trouble breathing) and PHARYNGEAL PARAESTHESIA (throat was tingly) outcome was unknown.    No treatment information was provided.    The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
I had taka cardia and atrial flutter Had a TEECG,  I had the 2nd dose of the monkey pox vaccine a couple weeks prior. I am scheduled for an appointment in June to potentially have an atrial ablations
Chills and then sweating (fever), nausea, then redness around site of injection. On Thursday has spread out into a star shape. A little sore where rash is. Only took some ibuprofen for pain and fever.
Mini Seizure and loss of consciousness (for about a minute) in response to first shot of Gardasil (HPV Vaccine)
I woke up with a really bad sore throat, congestion, mild fever. I took a home COVID-19 test that came back positive, I called and had a telehealth visit. I was prescribed Benzonatate for the cough, recommended some different cough medications, Molnupiravir (I did not take it) and an antibiotic (I did not take it). I did have a slight rash at the injection site but it only lasted for a day.
Headache; fatigue; nausea; muscle soreness; injection site pain; This is a spontaneous report from a contactable healthcare professional, the patient. A 32-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Lot EH9899) solution for injection in the left arm on 23Dec2020 at 13:30 (at the age of 32-years-old) as a single dose for COVID-19 vaccination. The patient was not pregnant at the time of vaccination. There was no medical history. Concomitant medications included amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (ADDERALL) and sertraline. The patient had no known allergies. The patient did not receive any other vaccine within 4 weeks prior to the vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 23Dec2020 at 18:00, the patient experienced headache, fatigue, nausea, muscle soreness, and injection site pain. No treatment was provided for the events headache, fatigue, nausea, muscle soreness, and injection site pain. The outcome of the events headache, fatigue, nausea, muscle soreness, and injection site pain was recovering. Since the vaccination, the patient has not been tested for COVID-19.
small red bumps on crook of right arm. Lasted a couple of days, majority gone now. As they disappeared they turned brown.
Pt seen on 10-19-2007 0930. Received flu in the late evening/night, noticed left arm (upper) swelling, redness, warm to touch, painful came to clinic on 10-22-2007. Seen by PAC. Recommends Tylenol/Motrin, ice pack, Benadryl
This spontaneous report was received from a nurse refers to two male infant patients of unknown age. No information about the patients' medical history, concurrent conditions and concomitant medications were not reported. On an unknown date, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB, strength: 2.5/ 0.5 (units unspecified), which had lot # L048236, expiry date: 31-MAR-2018 (dose and route not reported). One of the patient received a dose from the lot of RECOMBIVAX HB after it had been stored at 0.7 degree Celsius for 2 hours 30 minutes and the second patient received after it had been stored at -4 degree Celsius for 9 hours 45 minutes. No adverse effects were reported. Additional information has been requested.
Cerebral venous sinus thrombosis--Left transverse sinus, sigmoid sinus with extension into left internal jugular vein
Received fluvirin at 09:00 on 10/17/2003.  Developed hives around 16:00 that day.  Hives started at ankles then spread up legs and trunk.  Hives resolved in 36 hours.  Patient took Benadryl for hives.
Shortly after receiving the vaccine I started noticing a black dot that I thought was a gnat or fly only on one side in front of my eye. I received my shot in the right arm and that is the same side  the dot was appearing.
2.5 months since first dose; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (2.5 months since first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (2.5 months since first dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (2.5 months since first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment details were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 04-Jun-2021 and was forwarded to Moderna on 04-Jun-2021.    This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (2.5 months since first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (2.5 months since first dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (2.5 months since first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment details were reported.
8:00 PM, peripheral vision had colored lights on edge of vision field all the way around 5:30 AM on 2/12/21 (next day) extreme dizziness, mild headache, extreme fatigue Improvement in symptoms by 6:00 pm but persistent fatigue and off on headaches up until 2/20/21.
L arm swelling, redness, and numbness traveling up neck and L face.  L facial numbness, weakness, and swelling. L arm and L leg weakness. Aching, fever, chills, joint pains, body aches. can't move L face well.
PATIENT REPORTED FEELING AS IF LIPS WERE SWOLLEN. SHORTNESS OF BREATH AND DIFFICULTY SWALLOWING. RN ASSESSED AND GAVE 50 MG BENEDRYL AND EMS ALERTED.
Felt sick when he got the first 2 dose; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Felt sick when he got the first 2 dose) in a 34-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (Felt sick when he got the first 2 dose). At the time of the report, ILLNESS (Felt sick when he got the first 2 dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.   This case was linked to MOD-2021-398917, MOD-2021-398877 (Patient Link).
Blister inside my mouth; Face had blisters. Also had blisters on each ear; Blister on my upper lip, lower lip; Face had red blotches; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68-year-old male patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 13Oct2023 at 17:00 as dose 1, single (Batch/Lot number: unknown) at the age of 68 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Yes" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE), for COVID-19 immunisation; Covid-19 vaccine (DOSE 2, SINGLE), for COVID-19 immunisation; Covid-19 vaccine (DOSE 3 (BOOSTER), SINGLE), for COVID-19 immunisation; Covid-19 vaccine (DOSE 4 (BOOSTER), SINGLE), for COVID-19 immunisation. The following information was reported: ORAL MUCOSAL BLISTERING (medically significant) with onset 17Oct2023 at 12:00, outcome "recovering", described as "Blister inside my mouth"; LIP BLISTER (medically significant) with onset 17Oct2023 at 12:00, outcome "recovering", described as "Blister on my upper lip, lower lip"; BLISTER (medically significant) with onset 17Oct2023 at 12:00, outcome "recovering", described as "Face had blisters. Also had blisters on each ear"; RASH MACULAR (medically significant) with onset 17Oct2023 at 12:00, outcome "recovering", described as "Face had red blotches". The events "blister inside my mouth", "face had blisters. also had blisters on each ear", "blister on my upper lip, lower lip" and "face had red blotches" required emergency room visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (15Oct2023) Negative, notes: Nasal Swab. Therapeutic measures were taken as a result of oral mucosal blistering, blister, lip blister, rash macular. Clinical course: Patient reported that after 3 days of vaccination his face had red blotches and blisters. Also had blisters on each ear, but on his upper lip, lower lip and inside his mouth. On 23Oct2023. He went to hospital emergency room for sodium chloride IV (intravenous) and prednisone pills.  The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.
Vertigo, Ring in ears and pounding headaches Lasting for 5 days. Needed to be treated with steroids for 6 days. Outcome. Still having dizziness and ringing in ears .
A few hours after receiving a flu shot, my child's voice started to become hoarse. The hoarseness worsened over the next day, and into the following morning. She also had a lack of appetite, looser stools, and irritability. This all prompted me to take her to the doctor.
Patient began feeling flushed about 10 - 15 minutes after injection of 2nd Pfizer dose.  (patient had similar reaction after 1st dose but symptoms subsided after 30 minutes and left clinic with no further issues.)  This time however the patient rapidly began to decline and had tingling of the face with feeling of throat swelling and difficulty breathing.  When the patient began to gasp for air we quickly called 911 and administered an epi-pen 0.3mg  IM dose and 25 mg liquid diphenhydramine by mouth.  The patient quickly began to stabilize and a few minutes later the EMS arrived and took over the patients care.  After the EMS verified her vitals were stable she was transported to Hospital.  Patient was monitored there then discharged and sent home.  I checked on the patient post ER discharge and at one point she seemed to be feeling worse again so I instructed the family to administer 25mg diphenhydramine and return to the ER if the patient did not improve.  After a couple of hours I checked on the her again and she seemed to be resting and improving. I advised the family to continue to monitor her vitals and give fluids and return to the ER if necessary.
4 lesions in various stages including papules and 1 vesicle with onset 8 days after VARIVAX.
My husband and I both tested positive for Covid-19 after receiving the vaccine. He started to have symptoms like a cold, and it was like sinus symptoms. I also had sinus symptoms. He was prescribed Azithromycin and when it was gone a fever broke out. My husband throat was sore. He was admitted to the hospital and waited for a room for 24 hours. He was admitted directly to the Covid-19 ICU. He was tested again after being admitted on 07/10/2021 and he died on 08/06/2021. He had improved and he was supposed to come home and then I got a call that he had been intubated. He got Pneumonia after being on a ventilator. He lived for two more weeks but then he passed away.